Percorso Life Sciences (PLS) announces an agreement to represent Generation Biotech (GB) to commercialize its SNPSeq^TM product portfolio and provide strategic business development. PLS specializes in providing solutions to the business challenges of life science organizations seeking to enter or strengthen their commercial focus in the marketplace. Percorso partners with its clients to develop and execute innovative business and channel strategies calculated to maximize value within the client organization. Generation Biotech is a privately held biotechnology company whose proprietary magnetic bead-based haplotype- and region-specific extraction (HSE/RSE) allows the sequence-specific isolation of large DNA segments.

"We are proud to announce that Johannes Dapprich, Ph.D., president of Generation Biotech, has chosen PLS to provide strategic and commercial leadership at this phase of the organization’s development,” said Dino DiCamillo, CEO & president of PLS. "GB’s technology provides a unique solution to accurately identify causative variants and unambiguous molecular haplotypes that can build on existing SNP data. The ability of HSE/RSE to resolve difficult genetic variants has been proven in recent projects and publications, and the fact that a top-ranked pediatric hospital is evaluating its use for potential next generation sequencing-based clinical diagnostics is a testimony to the power of the technology to provide solutions to leading researchers in the scientific field,” added Mr. DiCamillo.

Back to the e-newsletter